Search
forLearn
5 / 801 resultsResearch
5 / 1000+ resultsresearch The Preclinical and Clinical Effects of Herbal Product Containing Rosa mutiflora Roots Extracts as a Main Component on the Hair Growth Promotion
Rosa multiflora root extract promotes hair growth and prevents hair loss.
research <p>Drinking Frequency but not Years may be Associated with Lower Urinary Tract Symptoms: Result from a Large Cross-Sectional Survey in Chinese Men</p>
Drinking alcohol 1-2 times a week may reduce urinary symptoms, but drinking more often might increase the risk.
research Sociodemographic predictors of outcomes in COVID-19: examining the impact of ethnic disparities in Northern Nevada
Hispanics in Northern Nevada had more COVID-19 cases but lower mortality than non-Hispanics.
research Sociodemographic Predictors of Outcomes in COVID-19: Examining the Impact of Ethnic Disparities in Northern Nevada
Hispanic individuals in Northern Nevada were more affected by COVID-19 but had lower mortality rates than non-Hispanics.
research Causes and management of Pica disorder among central Iraqi peoples
Pica disorder in central Iraq is mainly found in females and is linked to low iron levels; treatment with iron improves most patients.
Community Join
5 / 1000+ resultscommunity Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community hmi115 is coming. Prepare yourselves for what's coming
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community HMI-115 question about potential earliest access
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.